Unknown PHASE3 INTERVENTIONAL 2-arm NCT03023358

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Sponsor: Nanfang Hospital, Southern Medical University

Interventions chidamide cyclophosphamide liposomal doxorubicin prednisone vincristine

Updated 7 times since 2017 Last updated: Jan 13, 2017 Started: Feb 28, 2017 Primary completion: Mar 31, 2019 Completion: Mar 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Peripheral T Cell Lymphoma and is currently ongoing. Nanfang Hospital, Southern Medical University leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jul 2023 — Jul 2024 [monthly]

Unknown Status PHASE3
Jan 2021 — Jul 2023 [monthly]

Unknown Status PHASE3
Apr 2019 — Jan 2021 [monthly]

Unknown Status PHASE3

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Apr 2019 [monthly]

Not Yet Recruiting PHASE3
Feb 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nanfang Hospital, Southern Medical University

Data source: Nanfang Hospital, Southern Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China